Our Patents:

Luciano et al. patent 6,063,028 et patent 6,317,731

ABL is pleased to announce the acquisition and ownership of 2 US patents (Luciano – 6,063,028 and Luciano – 6,317,731) having as main inventor Dr Joanne Luciano.

Barry et al. patent 6,081,786 et patent 6,188,988

ABL is very pleased to report that a notice of allowance (2009 – 188754) has been issued by the Japanese Patent Office for the ABL patent “Systems, methods, and computer program products for guiding the selection of therapeutic treatment regimens”.
This patent is related to the ABL US Patents 6,081,786 and 6,188,988 from Barry et al. See the allowance
ABL has also received 2 new certificates following the re-examination requests for ABL US Patents 6,081,786 and 6,188,988. No claims were invalidated or amended for both patents.
New 6081786 patent certificate, New_6188988_patent_certificate

Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705

Advanced Biological Laboratories (ABL) SA, a Luxembourg-based company developing personalized medicine IT systems in the fields of infectious disease, is pleased to announce an exclusive and global license agreement with Emory University (Atlanta, Georgia) for the commercialization of a novel HIV-1 reverse transcriptase codon deletion and in all fields of use, including the management of HIV infections. Financial terms were not disclosed.ABL with this new licensing agreement continue strengthening its patent estate which is covering computational systems for personalized medicine in the field of chronic diseases such as, but not limited to, HIV/AIDS, liver diseases and affective disorders.
International Publication
http://www.emory.edu/home/index.html

Our Patent licensees :

Barry et al:

Vircolabs http://www.vircolab.com/
QuestDiagnostics http://www.questdiagnostics.com/ (PhenoScript HIV, developed by VirAlliance, subsidiary of Eurofins)
Evivar Medical http://www.evivar.com/ (Australia)

Luciano et al:

PREMED Inc http://www.predmed.com/products

Other agreement

Stanford University (cross immunity agreement).
U.S. Patent Number 6,503,705
U.S. Patent Number 5,856,086
U.S. Patent Number 5,650,268
U.S. Patent Number 5,631,128

News, Press releases (Patents)

South African Patent

ABL is pleased to report the South African Patent Office has been issued patent N° 2009/07533 and has been granted for 20 years from the filing date, April 10, 2008. This patent is related to the Emory Patent Internal Application WO/2008/124192.

Link to the issued patent

ABL is pleased to report the Canadian Patent Office has been issued patent N° 2326579 and has been granted for 20 years from the filing date, April 1, 1999.

This patent is related to the ABL US Patents 6,081,786 and 6,188,988 from Barry et al.
Link to the issued patent

ABL Announces the Strengthening of Its Patent Estate: Notice of Allowance in Canada, Issuance of a Patent in India, and Issuance of Reexamination Certificates in the United States after Several Patent Reexaminations

Updated Patents Certificates :Certificate for US Patent 6,081,788 (after first re-exam)
Certificate for US Patent 6,081,788 (after second re-exam)
Certificate for US Patent 6,188,988 (after first re-exam)
See the press release

ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform

LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA’s HIV resistance interpretation system.

ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge® HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient’s details and will support the healthcare providers’ virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.

See the press release

ABL Licensed CRP-Santé COMET Subtyping Tool

Advanced Biological Laboratories (ABL) S.A. and Luxembourg Centre de Recherche Public pour la Santé CRP-Santé announced a non-exclusive licensing and distribution agreement to implement CRP-Santé COMET subtyping tool on ABL TherapyEdge® Platform.

See the brochure

Centro de Genomas®

ABL is pleased to announce that Centro de Genomas® is as of Oct 15th 2009 the TherapyEdge® local agent in Brazil and will present the TherapyEdge® and ViroScore® products at the “XVI Congresso Brasileiro de Infectologia” which will be held from October the 18th to October the 21st at Maceió, BRAZIL.
See the brochure

The United States Patent & Trademark Office (USPTO)

ABL SA is pleased to announce the United States Patent & Trademark Office (USPTO) issued on September 15th 2009, the Ex Parte Reexamination Certificate for the Barry et al US patent N° 6,081,786
See the Ex Parte Reexamination Certificate here